Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma

Mary K. Lindemuth, David Euhus

Research output: Contribution to journalReview article

Abstract

Purpose of Review: The US Food and Drug Administration issued a recall of textured breast implants in July 2019 secondary to their association with anaplastic large cell lymphoma. This brief review serves to summarize what is actually known about breast implant associated anaplastic large cell lymphoma. Recent Findings: Since the FDA’s first preliminary report in 2011, there have been a reported worldwide total of 573 breast implant associated anaplastic large cell lymphoma (BIA-ALCL) cases, including 33 deaths. In addition to halting the implantation of textured implants, the July recall served to increase awareness and vigilance when caring for patients with a history of textured breast implants. Recommendations continue to be against voluntary implant removal. Summary: In the setting of the FDA recall, the importance of comprehensive counseling remains paramount. For patients with textured breast implants, it is vital to ensure patient awareness with thorough education on warning signs and the importance of follow-up.

Original languageEnglish (US)
JournalCurrent Breast Cancer Reports
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Anaplastic Large-Cell Lymphoma
Breast Implants
United States Food and Drug Administration
Counseling
Education

Keywords

  • Breast implant-associated lymphoma
  • Current guidelines
  • Diagnosis
  • Pathogenesis
  • Textured breast implants
  • Treatment

ASJC Scopus subject areas

  • Oncology

Cite this

Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma. / Lindemuth, Mary K.; Euhus, David.

In: Current Breast Cancer Reports, 01.01.2019.

Research output: Contribution to journalReview article

@article{3221598d6a8b41ea85cddb037cad727f,
title = "Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma",
abstract = "Purpose of Review: The US Food and Drug Administration issued a recall of textured breast implants in July 2019 secondary to their association with anaplastic large cell lymphoma. This brief review serves to summarize what is actually known about breast implant associated anaplastic large cell lymphoma. Recent Findings: Since the FDA’s first preliminary report in 2011, there have been a reported worldwide total of 573 breast implant associated anaplastic large cell lymphoma (BIA-ALCL) cases, including 33 deaths. In addition to halting the implantation of textured implants, the July recall served to increase awareness and vigilance when caring for patients with a history of textured breast implants. Recommendations continue to be against voluntary implant removal. Summary: In the setting of the FDA recall, the importance of comprehensive counseling remains paramount. For patients with textured breast implants, it is vital to ensure patient awareness with thorough education on warning signs and the importance of follow-up.",
keywords = "Breast implant-associated lymphoma, Current guidelines, Diagnosis, Pathogenesis, Textured breast implants, Treatment",
author = "Lindemuth, {Mary K.} and David Euhus",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12609-019-00336-0",
language = "English (US)",
journal = "Current Breast Cancer Reports",
issn = "1943-4588",
publisher = "Current Science, Inc.",

}

TY - JOUR

T1 - Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma

AU - Lindemuth, Mary K.

AU - Euhus, David

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose of Review: The US Food and Drug Administration issued a recall of textured breast implants in July 2019 secondary to their association with anaplastic large cell lymphoma. This brief review serves to summarize what is actually known about breast implant associated anaplastic large cell lymphoma. Recent Findings: Since the FDA’s first preliminary report in 2011, there have been a reported worldwide total of 573 breast implant associated anaplastic large cell lymphoma (BIA-ALCL) cases, including 33 deaths. In addition to halting the implantation of textured implants, the July recall served to increase awareness and vigilance when caring for patients with a history of textured breast implants. Recommendations continue to be against voluntary implant removal. Summary: In the setting of the FDA recall, the importance of comprehensive counseling remains paramount. For patients with textured breast implants, it is vital to ensure patient awareness with thorough education on warning signs and the importance of follow-up.

AB - Purpose of Review: The US Food and Drug Administration issued a recall of textured breast implants in July 2019 secondary to their association with anaplastic large cell lymphoma. This brief review serves to summarize what is actually known about breast implant associated anaplastic large cell lymphoma. Recent Findings: Since the FDA’s first preliminary report in 2011, there have been a reported worldwide total of 573 breast implant associated anaplastic large cell lymphoma (BIA-ALCL) cases, including 33 deaths. In addition to halting the implantation of textured implants, the July recall served to increase awareness and vigilance when caring for patients with a history of textured breast implants. Recommendations continue to be against voluntary implant removal. Summary: In the setting of the FDA recall, the importance of comprehensive counseling remains paramount. For patients with textured breast implants, it is vital to ensure patient awareness with thorough education on warning signs and the importance of follow-up.

KW - Breast implant-associated lymphoma

KW - Current guidelines

KW - Diagnosis

KW - Pathogenesis

KW - Textured breast implants

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85074845303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074845303&partnerID=8YFLogxK

U2 - 10.1007/s12609-019-00336-0

DO - 10.1007/s12609-019-00336-0

M3 - Review article

AN - SCOPUS:85074845303

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

SN - 1943-4588

ER -